

MGFA International Conference Poster Key - Summary Guide

Poster Number	First Author Last Name	First Author First Name	Room Location on Floor	Abstract Title
1	Akinsanmi, et.al.	Danielle	Congress 4	SYNCOPE AS A PRESENTING SYMPTOM OF MUSK-ASSOCIATED MYASTHENIA GRAVIS: A CASE REPORT
2	Aktas, et.al.	Cemre	Congress 4	ALTERED B CELL SIGNALING AND RESPONSES TO T FOLLICULAR HELPER CELL-RELATED CYTOKINES IN MYASTHENIA GRAVIS
3	Amini, et.al.	Fatemeh	Congress 4	A NOVEL INTERNATIONAL PATIENT REGISTRY IN MYASTHENIA GRAVIS LINKING CLINICAL AND PATIENT-REPORTED OUTCOMES DATA: THE VITACCESS REAL MG (VRMG) REGISTRY
4	Antozzi, et.al.	Carlo	Congress 4	PATIENT PREFERENCES AND EXPERIENCE WITH SELF-ADMINISTRATION OF ROZANOLIXIZUMAB IN GENERALISED MYASTHENIA GRAVIS
5	Antozzi, et.al.	Carlo	Congress 4	LONG-TERM SAFETY AND EFFICACY OF NIPOCALIMAB IN GENERALIZED MYASTHENIA GRAVIS: VIVACITY-MG3 OPEN-LABEL EXTENSION PHASE RESULTS
6	Antozzi, et.al.	Carlo	Congress 4	EFGARTIGIMOD CHANGES THE COURSE OF ACHR AND NON-ACHR MYASTHENIA GRAVIS

7	Antozzi, et.al.	Carlo	Congress 4	THE ITALIAN MYASTHENIA GRAVIS REGISTRY
8	Antozzi, et.al.	Carlo	Congress 4	IDENTIFICATION OF CLINICAL VARIABLES ASSOCIATED WITH TREATMENT RESPONSE TO EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS
9	Arets, et.al.	Britt	Congress 4	UPDATED GUIDELINES ON THE PASSIVE TRANSFER MYASTHENIA GRAVIS RAT MODEL: THE ADVANTAGES OF SUBCUTANEOUS ADMINISTRATION
10	Aydin, et.al.	Gozde	Congress 4	CO-DESIGN OF DISCRETE CHOICE EXPERIMENT SURVEY WITH MYASTHENIA GRAVIS PATIENTS USING NOMINAL GROUP TECHNIQUE AND FOCUS GROUPS
11	Baheerathan, et.al.	Aravindhan	Congress 4	EFGARTIGIMOD FOR TREATMENT REFRACTORY ACETYLCHOLINE RECEPTOR ANTIBODY POSITIVE MYASTHENIA GRAVIS: THE NATIONAL HOSPITAL FOR NEUROLOGY & NEUROSURGERY EXPERIENCE
12	Baheerathan, et.al.	Aravindhan	Congress 4	RITUXIMAB FOR GENERALISED MYASTHENIA GRAVIS: A SINGLE CENTRE EXPERIENCE OF SAFETY, TOLERABILITY AND EFFICACY
13	Bakker, et.al.	Wisse	Congress 4	LONGITUDINAL OVERVIEW OF SYMPTOMATIC AND IMMUNOSUPPRESSIVE DRUGS IN LEMS

14	Barnett-Tapia, et.al.	Carolina	Congress 4	DESIGN OF A PHASE 3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 ADMINISTERED BY PREFILLED SYRINGE IN ADULTS WITH OCULAR MYASTHENIA GRAVIS
15	Beaupark, et.al.	Suzann	Congress 4	DEVELOPING A PATIENT LIVED EXPERIENCE RESEARCHER TOOLKIT FOR ENGAGING COLLABORATIVE CLINICAL ASSISTANCE: PILOT STUDY ON NEW DIAGNOSTIC EYE TESTS
16	Beretta, et.al.	Francesca	Congress 4	CLINICAL AND SEROLOGIC CHARACTERISTICS OF SERONEGATIVE MYASTHENIA GRAVIS: AN ITALIAN MULTICENTER STUDY
17	Betts, et.al.	April	Congress 4	ZILUCOPLAN VERSUS ECULIZUMAB AND RAVULIZUMAB FOR TREATING GENERALISED MYASTHENIA GRAVIS: MATCHING-ADJUSTED INDIRECT COMPARISONS
18	Bilgin, et.al.	Seyda	Congress 4	REGULATORY FEATURES OF CD8 ⁺ T CELLS IN MYASTHENIA GRAVIS
19	Biran, et.al.	Yifat	Congress 4	WE VALUE EVERYONE'S PLACE AT THE TABLE
20	Birnbaum, et.al.	Simone	Congress 4	FATIGABILITY IN AUTOIMMUNE MYASTHENIA GRAVIS: FACT OR FICTION? A SCOPING REVIEW OF EXISTING LITERATURE

21	Birnbaum, et.al.	Simone	Congress 4	“WHY AM I SHORT OF BREATH?” A PROSPECTIVE STUDY TO EVALUATE DYSPNEA IN ADULTS WITH AUTOIMMUNE MYASTHENIA GRAVIS: THE MYARESP STUDY PROTOCOL.
22	Ghandi, et.al.	Kavita	Congress 4	REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
23	Brandhøj Skov, et.al.	Martin	Congress 4	THE SKELETAL MUSCLE SPECIFIC CHLORIDE-1 ION CHANNEL (CLC-1) REGULATES THE MUSCLE’S ABILITY TO ACTIVATE AND THEREFORE REPRESENTS A VIABLE COMPLEMENTARY THERAPEUTIC TARGET TO IMMUNOSUPPRESSANTS AND IMMUNOMODULATORY AGENTS
24	Businaro, et.al.	Pietro	Congress 4	FREQUENCY OF LRP4 ANTIBODIES IN A CONSECUTIVE COHORT OF SUSPECTED MYASTHENIA GRAVIS PATIENTS
25	Businaro, et.al.	Pietro	Congress 4	OPTIMIZATION OF A SCREENING ASSAY FOR ANTIBODY-MEDIATED COMPLEMENT ACTIVATION (ACA) IN AUTOIMMUNE NEUROLOGICAL DISORDERS
26	Cabraal, et.al.	Isobel	Congress 4	EPIDEMIOLOGY OF ACHR-IGG AND MUSK-IGG SEROPOSITIVE MYASTHENIA GRAVIS IN OXFORDSHIRE, UK (2011-2023)
27	Camera, et.al.	Giorgia	Congress 4	EFFICACY OF RAVULIZUMAB IN LONG-STANDING MYASTHENIA GRAVIS

28	Cavalcante, et.al.	Paola	Congress 4	MIRNA-MRNA-LNCRNA NETWORKS MODULATING T AND B CELL PROLIFERATION CONTRIBUTE TO UNRESPONSIVENESS TO IMMUNOSUPPRESSIVE DRUGS IN MYASTHENIA GRAVIS
29	Chen, et.al.	Jia Xin	Congress 4	EFFECTS OF THYMECTOMY IN LATE-ONSET MYASTHENIA GRAVIS: A MULTI-CENTER LONGITUDINAL RETROSPECTIVE STUDY
30	Chen, et.al.	Pei	Congress 4	COMBINED USE OF MAGNETIZATION TRANSFER RATIO AND T2-MAPPING TO EVALUATE EXTRAOCULAR MUSCLE PATHOPHYSIOLOGY IN MYASTHENIA GRAVIS WITH OPHTHALMOPARESIS
31	Choudhry, et.al.	Zia	Congress 4	IDENTIFYING RISK FACTORS FOR EXACERBATION AND SYMPTOM WORSENING—A RETROSPECTIVE COHORT STUDY OF PATIENTS WITH MYASTHENIA GRAVIS IN THE UNITED STATES
32	Rospars, et.al.	Brindley	Congress 4	MAPPING OUT THE PATIENT JOURNEY OF GENERALIZED MYASTHENIA GRAVIS: INSIGHTS AND CHALLENGES
33	Rospars, et.al.	Brindley	Congress 4	PARTNERING WITH PATIENTS AND CAREGIVERS TO GUIDE THE DEVELOPMENT OF IMPACTFUL STUDY ENGAGEMENT TOOLS IN A GENERALIZED MYASTHENIA GRAVIS REAL-WORLD STUDY
34	Cornacchini, et.al.	Sara	Congress 4	SINGLE FIBER EMG IN THE DIAGNOSTIC WORKUP OF DIPLOPIA AND PTOSIS

35	D'Alvano, et.al.	Giulia	Congress 4	RAPID EFFICACY OF ECULIZUMAB IN PATIENTS WITH REFRACTORY GENERALIZED MYASTHENIA GRAVIS: A SINGLE-CENTER STUDY
36	Desai, et.al.	Urvi	Congress 4	IMMUNE CHECKPOINT INHIBITOR ASSOCIATED SERONEGATIVE POST SYNAPTIC NMJ DISORDER: A CASE REPORT AND LITERATURE REVIEW
37	Dodd, et.al.	Katherine	Congress 4	REFRACTORY MYASTHENIA GRAVIS CHARACTERISED BY WIDESPREAD INNATE AND ADAPTIVE IMMUNE SYSTEM CHANGES
38	Dragin, et.al.	Nadine	Congress 4	MOLECULAR AND METABOLIC ANALYSES OF ACHR+ MG SKELETAL MUSCLES
39	Du, et.al.	Peng	Congress 4	REFINING THE METHODOLOGY TO STUDY ANTIBODY-INDUCED ACETYLCHOLINE RECEPTOR MODULATION IN MYASTHENIA GRAVIS
40	Durmus, et.al.	Hacer	Congress 4	ECULIZUMAB AS A RESCUE THERAPY IN MYASTHENIC CRISIS IN ICU
41	Durmus, et.al.	Hacer	Congress 4	ECULIZUMAB VERSUS RITUXIMAB FOR REFRACTORY ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY-POSITIVE GENERALIZED MYASTHENIA GRAVIS: A SINGLE-CENTER EXPERIENCE

42	Engelbrecht, et.al.	Charlotte	Congress 4	DEVELOPMENT OF THE MYASTHENIA GRAVIS-HEALTH INDEX (MG-HI), A REGULATORY-GRADE PATIENT-REPORTED OUTCOME MEASURE
43	Eriksson Dufva, et.al.	Ann	Congress 4	INTERLEUKIN-6 INHIBITION IN MYASTHENIA GRAVIS; A CASE SERIES EXPOSED TO TOCILIZUMAB
44	Erra, et.al.	Carmen	Congress 4	A SINGLE CENTER EXPERIENCE IN THE USE OF RITUXIMAB IN MYASTHENIA GRAVIS WITH LONG-TERM FOLLOW UP
45	Falso, et.al.	Silvia	Congress 4	MYASTHENIA GRAVIS MISDIAGNOSIS: UNCOVERING THE PITFALLS AND PATTERNS
46	Falso, et.al.	Silvia	Congress 4	THE EVOLVING LANDSCAPE OF MUSK-MG EPIDEMIOLOGY AND TREATMENT
47	Forstein, et.al.	Agatha	Congress 4	EVALUATING THE EVIDENCE BEHIND THE MYASTHENIA GRAVIS MEDICATION OF CAUTION LIST
48	Frangiamore, et.al.	Rita	Congress 4	COMPLEMENT INHIBITION FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS: A REAL WORLD EXPERIENCE WITH RAVULIZUMAB

49	Freimer, et.al.	Miriam	Congress 4	SWITCHING TO SUBCUTANEOUS ZILUCOPLAN FROM INTRAVENOUS COMPLEMENT INHIBITORS IN GMG: PATIENT PREFERENCE AND SATISFACTION FROM A PHASE 3B STUDY
50	Fribert, et.al.	Charlotte	Congress 4	A PHASE I/IIA FIRST-IN-HUMAN STUDY OF TOL2, AN IMMUNE TOLERISING AGENT, IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
51	Fuhr, et.al.	Alexis	Congress 4	INVESTIGATING THE BIOEQUIVALENCE, INJECTION SPEED, AND USABILITY OF SUBCUTANEOUS EFGARTIGIMOD PH20 ADMINISTRATION USING A PREFILLED SYRINGE
52	Gamez, et.al.	Josep	Congress 4	MYASTHENIA GRAVIS CONCURRENT WITH PARKINSON'S DISEASE. A REPORT OF 18 CASES
53	Gandhi, et.al.	Kavita	Congress 4	DISEASE BURDEN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
54	Gandhi, et.al.	Kavita	Congress 4	COMPOSITE RESPONSE TO NIPOCALIMAB, A NOVEL FCRN BLOCKER, BASED ON MG-ADL AND QUANTITATIVE MG SCORES IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
55	Gandhi, et.al.	Kavita	Congress 4	EFFICACY OF NIPOCALIMAB, A NOVEL FcRn BLOCKER, AS MEASURED USING QUANTITATIVE MYASTHENIA GRAVIS ASSESSMENT: FINDINGS FROM PHASE 3 VIVACITY-MG3 STUDY

56	Gandhi, et.al.	Kavita	Congress 4	ECONOMIC BURDEN OF MYASTHENIA GRAVIS EXACERBATION AND CRISIS FROM US PAYER PERSPECTIVE
57	Gandhi, et.al.	Kavita	Congress 4	LONG-TERM USE OF ORAL CORTICOSTEROIDS AND OVERALL SURVIVAL AMONG PATIENTS WITH MYASTHENIA GRAVIS: A NATIONWIDE POPULATION-BASED STUDY
58	Gandhi, et.al.	Kavita	Congress 4	SAFETY PROFILE OF NIPOCALIMAB, A NEW NEONATAL FRAGMENT CRYSTALLIZABLE RECEPTOR BLOCKER IN THE PHASE 3 VIVACITY STUDY
59	Gerischer, et.al.	Lea	Congress 4	COMPLEMENT INHIBITION IN SEVERE MYASTHENIC CRISIS – A RETROSPECTIVE MULTICENTER ANALYSIS OF 17 CASES IN GERMANY
60	Giacopuzzi, et.al.	Eleonora	Congress 4	TREATMENTS FOR GENERALIZED MYASTHENIA GRAVIS: RAPID IMPROVEMENT IN TWO ACHR-AB POSITIVE PATIENTS TREATED WITH SUBCUTANEOUS ZILUCOPLAN IN A REAL-WORLD SETTING.
61	Gómez-Ballesteros, et.al.	Rocío	Congress 4	UNDERSTANDING NEUROLOGISTS' PREFERENCES FOR TREATMENT ATTRIBUTES IN MANAGING GENERALIZED MYASTHENIA GRAVIS
62	Gómez-Ballesteros, et.al.	Rocío	Congress 4	IMPORTANCE OF BODILY FUNCTIONS IN GENERALIZED MYASTHENIA GRAVIS FROM NEUROLOGISTS' PERSPECTIVE

63	Goyal, et.al.	Neelam	Congress 4	ASSESSING GLUCOCORTICOID ASSOCIATED TOXICITY IN MYASTHENIA GRAVIS USING THE GLUCOCORTICOID TOXICITY INDEX
64	Goyal, et.al.	Neelam	Congress 4	REAL-WORLD REDUCTION IN ORAL CORTICOSTEROID UTILIZATION AT 1-YEAR FOLLOWING EFGARTIGIMOD INITIATION
65	Greco, et.al.	Giulia	Congress 4	EXPLORING THE CORRELATIONS BETWEEN FATIGUE, DEPRESSION, SLEEP DISORDERS AND CLINICAL SEVERITY IN MG PATIENTS
66	Grosskreutz, et.al.	Julian	Congress 4	THE SAFETY AND EFFICACY OF CHRONIC WEEKLY ROZANOLIXIZUMAB TREATMENT IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS (MG0004)
67	Gwathmey, et.al.	Kelly	Congress 4	EVALUATION OF THE INDIRECT AND NONMEDICAL IMPACTS OF GMG ON PATIENTS AND CAREGIVERS
68	Gwathmey, et.al.	Kelly	Congress 4	HUMAN FACTORS VALIDATION STUDY OF GEFURULIMAB PREFILLED SYRINGE AND AUTOINJECTOR DEVICES
69	Gwathmey, et.al.	Kelly	Congress 4	THE MYASTHENIA GRAVIS PATIENT REGISTRY: CHARACTERISTICS, INSIGHTS, AND LEARNINGS AFTER A DECADE (2013-2023)

70	Habib, et.al.	Ali	Congress 4	RESET-MG: A PHASE 1/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELLS (CABA 201) IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS
71	Habib, et.al.	Ali	Congress 4	EFFICACY AND SAFETY OF ROZANOLIXIZUMAB TREATMENT CYCLES IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: FINAL POOLED ANALYSIS OF PHASE 3 STUDIES
72	Habib, et.al.	Ali	Congress 4	ROZANOLIXIZUMAB TREATMENT PATTERNS IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: POST HOC ANALYSIS
73	Habib, et.al.	Ali	Congress 4	DEVELOPMENT OF THE QUANTITATIVE MYASTHENIA GRAVIS-REVISED SCORE (QMG-R) TRAINING VIDEOS: IMPROVING CONSISTENCY THROUGH STANDARDIZED INSTRUCTIONS FOR CLINICAL TRIALS
74	Habib, et.al.	Ali	Congress 4	FIXED CYCLE AND EVERY-OTHER-WEEK DOSING OF INTRAVENOUS EFGARTIGIMOD FOR GENERALIZED MYASTHENIA GRAVIS: PART B OF ADAPT NXT
75	Harborth, et.al.	Elena	Congress 4	PREVALENCE AND SEVERITY OF DYSPHAGIA IN PATIENTS WITH MYASTHENIA GRAVIS ASSESSED BY FLEXIBLE ENDOSCOPIC EVALUATION OF SWALLOWING (FEES)
76	He, et.al.	Dingxian	Congress 4	RESPONSE OF REFRACTORY RESIDUAL OCULAR SYMPTOMS TO EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS: A REAL-WORLD CASE SERIES

77	Schmidt, et.al.	Jens	Congress 4	CONCOMITANT INTRAVENOUS IMMUNOGLOBULIN OR PLASMA EXCHANGE HAS NO EFFECT ON COMPLEMENT INHIBITION BY ZILUCOPLAN
78	Heerlein, et.al.	Kristin	Congress 4	COMBINED ANALYSES OF PARTICIPANTS TREATED WITH EFGARTIGIMOD EARLY IN THE COURSE OF GENERALIZED MYASTHENIA GRAVIS ACROSS CLINICAL STUDIES
79	Hemery, et.al.	Edouard	Congress 4	DECIPHERING THE ROLE OF MONONUCLEAR PHAGOCYTES IN THYMIC INFLAMMATION IN MYASTHENIA GRAVIS
80	Hernandez, et.al.	Amanda	Congress 4	RECURRENT SUBCONJUNCTIVAL HEMORRHAGE FOLLOWING EFGARTIGIMOD TREATMENT IN OCULAR MYASTHENIA GRAVIS: A UNIQUE CASE REPORT
81	Hernandez, et.al.	Amanda	Congress 4	CASE REPORT: CLINICAL IMPROVEMENT IN NON-THYMOMATOUS ANTI-RYANODINE RECEPTOR (ANTI-RYR) POSITIVE GENERALIZED MYASTHENIA GRAVIS WITH EFGARTIGIMOD INTRAVENOUS INFUSIONS
82	Hernandez, et.al.	Amanda	Congress 4	CASE REPORT: CLINICAL BENEFIT OF FIRST CYCLE OF ROZANOLIXIZUMAB INFUSIONS IN NON-THYMOMATOUS ANTI-TITIN POSITIVE GENERALIZED MYASTHENIA GRAVIS
83	Hewamadduma, et.al.	Channa	Congress 4	EARLY AND SUSTAINED RESPONSE OVER TIME WITH ZILUCOPLAN IN GENERALISED MYASTHENIA GRAVIS: 120-WEEK POST HOC ANALYSIS OF RAISE-XT

84	Hewamadduma, et.al.	Channa	Congress 4	CORTICOSTEROID DOSE TAPERING DURING TREATMENT WITH ZILUCOPLAN IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: 120-WEEK FOLLOW-UP OF RAISE-XT
85	Hoffmann, et.al.	Sarah	Congress 4	IDENTIFICATION GENDER DIFFERENCES IN AUTOIMMUNE MYASTHENIA GRAVIS USING MACHINE LEARNING MODELS
86	Hoffmann, et.al.	Sarah	Congress 4	EARLY AND HIGH-DOSE MATERNAL-FETAL THERAPY TO PREVENT REPEATED FETAL ACETYLCHOLINE RECEPTOR ANTIBODY-RELATED DISORDER (FARAD)
87	Hoichman, et.al.	Garrick	Congress 4	IMMUNE CHECKPOINT DOWNREGULATION AND NEGATIVE CORRELATION OF TIGIT EXPRESSION WITH ADL SCORES IN MYASTHENIA GRAVIS
88	Holland, et.al.	Stephen	Congress 4	GALACTOSE SUPPLEMENTATION RESCUES PROTEIN GLYCOSYLATION AND NEUROMUSCULAR PHENOTYPE IN GLUTAMINE-FRUCTOSE-6-PHOSPHATE TRANSAMINASE 1 CONGENITAL MYASTHENIC SYNDROME (GFPT1-CMS)
89	Howard, et.al.	James	Congress 4	THE PHASE 3 PREVAIL STUDY ASSESSING THE EFFICACY AND SAFETY OF GEFURULIMAB IN GMG: TRIAL IN PROGRESS
90	Howard, et.al.	James	Congress 4	DEVELOPING NEEDS-DRIVEN MEDICAL EDUCATION FOR HEALTHCARE PROFESSIONALS IN MYASTHENIA GRAVIS

91	Howard, et.al.	James	Congress 4	PHASE 3 TRIAL INVESTIGATING IMPACT OF INTRAVENOUS EFGARTIGIMOD IN ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY NEGATIVE GENERALIZED MYASTHENIA GRAVIS
92	Huang, et.al.	Yu-Fang	Congress 4	PHARMACOLOGICAL ANALYSIS OF ACETYLCHOLINE RECEPTORS IN A HUMAN MUSCLE CELL MODEL OF MYASTHENIA GRAVIS USING LIVE-CELL CALCIUM IMAGING
93	Huntemann, et.al.	Niklas	Congress 4	COMPARISON OF C5 COMPLEMENT INHIBITION VERSUS FCRN ANTAGONISM IN GENERALIZED MYASTHENIA GRAVIS
94	Iacomino, et.al.	Nicola	Congress 4	B CELL-RELATED GENE VARIANTS AS PERSONALIZED MEDICINE BIOMARKERS TO PREDICT UNRESPONSIVENESS TO IMMUNOSUPPRESSIVE DRUGS IN MYASTHENIA GRAVIS
95	Jacob, et.al.	Saiju	Congress 4	ASSOCIATION OF BRITISH NEUROLOGISTS (ABN) AUTOIMMUNE MYASTHENIA GRAVIS MANAGEMENT GUIDELINES (2025 UPDATE)
96	Jakobsgaard, et.al.	Jesper Emil	Congress 4	EXTENSIVE PHENOTYPING OF A RAT MUSK MYASTHENIA GRAVIS MODEL – FROM NEUROMUSCULAR IN VIVO FUNCTION TO MOLECULAR PROPERTIES
97	Jensen, et.al.	Stine Marie	Congress 4	PATIENT-SPECIFIC THERAPEUTIC BENEFIT OF MUSCLE-SPECIFIC KINASE (MuSK) AGONIST ANTIBODY ARGX-119 IN MuSK MYASTHENIA GRAVIS PASSIVE TRANSFER MODELS

98	Jin, et.al.	Lei	Congress 2/3	PATTERNS AND PREDICTORS OF THERAPEUTIC RESPONSE TO EFGARTIGIMOD IN ACETYLCHOLINE RECEPTOR-ANTIBODY GENERALIZED MYASTHENIA GRAVIS SUBTYPES
99	Jul Jarbæk Nielsen, et.al.	Josefine	Congress 2/3	ASSOCIATED AUTOIMMUNITY IN MYASTHENIA GRAVIS IN DENMARK: A NATIONWIDE CASE-CONTROL STUDY
100	Jul Jarbæk Nielsen, et.al.	Josefine	Congress 2/3	ASSOCIATION OF RECENT INFECTION AND SUBSEQUENT MYASTHENIA GRAVIS: A NATIONWIDE CASE-CONTROL STUDY FROM 1985 TO 2020
101	Kaminski, et.al.	Henry	Congress 2/3	TOWARDS A DIGITAL TWIN FOR MYASTHENIA GRAVIS
102	Keritam, et.al.	Omar	Congress 2/3	IDENTIFICATION OF CONGENITAL MYASTHENIC SYNDROMES IN A SERONEGATIVE MYASTHENIA GRAVIS COHORT
103	Khani-Habibabadi, et.al.	Fatemeh	Congress 2/3	DISTRIBUTION AND TEMPORAL CHANGES OF AUTOANTIBODY-MEDIATED PATHOGENIC MECHANISMS AMONG ACHR-POSITIVE MYASTHENIA GRAVIS PATIENTS
104	Kim, et.al.	Seung Woo	Congress 2/3	CLINICAL CHARACTERISTICS AND TREATMENT STATUS OF THE PATIENTS WITH MYASTHENIA GRAVIS: A SINGLE-CENTER EXPERIENCE

105	Kiyasova, et.al.	Vera	Congress 2/3	POST-HOC RESPONDER ANALYSES FROM THE PROOF-OF-MECHANISM STUDY OF NMD670 IN PATIENTS WITH MYASTHENIA GRAVIS
106	Kiyasova, et.al.	Vera	Congress 2/3	PHASE 2B STUDY DESIGN FOR NMD670, A FIRST-IN-CLASS CLC-1 INHIBITOR IN GENERALIZED MYASTHENIA GRAVIS: THE SYNAPSE-MG DOSE-FINDING STUDY
107	Kotay, et.al.	Manisha	Congress 2/3	MY GUESS IS AS GOOD AS YOURS: FACTORS CONTRIBUTING TO DIAGNOSIS AND OVERDIAGNOSIS OF MYASTHENIA GRAVIS
108	Kusner, et.al.	Linda	Congress 2/3	WHOLE BLOOD TRANSCRIPTIONAL PROFILES FROM THE MGTX TRIAL REVEAL POTENTIAL MECHANISMS OF THYMECTOMY BENEFIT
109	Lawton, et.al.	Catherine	Congress 2/3	EVALUATION OF MEASURES FOR OCULAR MANIFESTATIONS IN MYASTHENIA GRAVIS
110	Leite, et.al.	Maria	Congress 2/3	IMPROVEMENT OF OCULAR SUBDOMAIN SCORES WITH ZILUCOPLAN IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS IN RAISE AND RAISE-XT STUDIES
111	Leite, et.al.	Maria	Congress 2/3	LONG-TERM PROPHYLACTIC ANTIBIOTIC USE IN ADDITION TO MENINGOCOCCAL VACCINES DURING ZILUCOPLAN TREATMENT: SINGLE SITE EXPERIENCE FROM PHASE 3 STUDIES

112	Li, et.al.	Mingming	Congress 2/3	IDENTIFICATION OF NOVEL BIOMARKERS FOR MYASTHENIA GRAVIS DISEASE AND PROGRESSION
113	Lindroos, et.al.	Jenny	Congress 2/3	MEDICATION USE BEFORE, DURING AND AFTER PREGNANCY IN A POPULATION-BASED COHORT OF NORWEGIAN AND SWEDISH WOMEN WITH MYASTHENIA GRAVIS
114	Lippens, et.al.	Léa	Congress 2/3	DEVELOPMENT OF A REFINED EXPERIMENTAL AChR-MG MOUSE MODEL
115	Lochmuller, et.al.	Hanns	Congress 2/3	MULTICENTER, MULTINATIONAL, NATURAL HISTORY STUDY IN PARTICIPANTS WITH DOK7 CONGENITAL MYASTHENIC SYNDROMES
116	Lotti, et.al.	Antonio	Congress 2/3	IMMUNE CHECKPOINT INHIBITORS-RELATED MYASTHENIA, MYOSITIS AND MYOCARDITIS: A SINGLE CENTER EXPERIENCE
117	Lytton, et.al.	Simon	Congress 2/3	TARGETING THE HUMAN NICOTINIC ACETYLCHOLINE RECEPTOR BY NOVEL RECOMBINANT HUMAN MONOCLONAL AUTOANTIBODY
118	Maggi, et.al.	Lorenzo	Congress 2/3	DAILY EVALUATION OF EARLY EFFECT OF INNOVATIVE THERAPIES IN GENERALIZED MYASTHENIA GRAVIS IN THE FIRST WEEK OF TREATMENT

119	Mane, et.al.	Marina	Congress 2/3	HOCK IMMUNIZATION, A REFINED ALTERNATIVE TO DEVELOPING EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS IN MICE. A GUIDELINES' UPDATE.
120	Marini, et.al.	Sofia	Congress 2/3	COMPLEMENT INHIBITOR THERAPY IN THYMOMA-ASSOCIATED MYASTHENIA GRAVIS: A REAL-WORLD EXPERIENCE
121	Marini, et.al.	Sofia	Congress 2/3	INVESTIGATING THE EFFECT OF MENINGOCOCCAL VACCINATION IN PATIENTS WITH MYASTHENIA GRAVIS UNDERGOING COMPLEMENT INHIBITOR THERAPY
122	McInnes, et.al.	Abigail	Congress 2/3	DOSE-DEPENDENT PHENOTYPIC CORRECTION OF COLQ-DEFICIENT MICE BY ADENO-ASSOCIATED VIRUS TYPE RH74-MEDIATED GENE THERAPY
123	Meisel, et.al.	Andreas	Congress 2/3	ADAPTATION OF THE MYASTHENIA GRAVIS SYMPTOM PATIENT-REPORTED OUTCOME SCALES FOR USE IN CLINICAL PRACTICE, CLINICAL STUDIES AND OBSERVATIONAL STUDIES
124	Miller-Wilson, et.al.	Lesley-Ann	Congress 2/3	CLINICAL OUTCOMES AND EVENTS IN A UNITED STATES GENERALIZED MYASTHENIA GRAVIS POPULATION: ANALYSIS OF REAL-WORLD DATA
125	Miller-Wilson, et.al.	Lesley-Ann	Congress 2/3	TREATMENT PATTERNS OF A UNITED STATES GENERALIZED MYASTHENIA GRAVIS POPULATION: ANALYSIS OF REAL-WORLD DATA

126	Miller-Wilson, et.al.	Lesley-Ann	Congress 2/3	PATIENT-REPORTED OUTCOMES FROM A SURVEY OF REAL-WORLD GENERALIZED MYASTHENIA GRAVIS PATIENTS IN THE UNITED STATES
127	Morcone, et.al.	Veronica	Congress 2/3	ESTABLISHING STABLE ACETYLCHOLINE RECEPTOR EXPRESSION IN RD CELLS USING THE PIGGYBAC SYSTEM: IMPROVING PLATFORMS FOR FUNCTIONAL ASSAYS
128	Morena, et.al.	Jonathan	Congress 2/3	AZATHIOPRINE TOXICITY IN PATIENTS WITH MYASTHENIA GRAVIS: A SINGLE CENTER EXPERIENCE
129	Mousavi, et.al.	Ali	Congress 2/3	THE INCIDENCE OF MYASTHENIA GRAVIS IN THE PROVINCE OF BRITISH COLUMBIA, CANADA FROM JANUARY 2004 TO DECEMBER 2023
130	Mousavi, et.al.	Ali	Congress 2/3	DEVELOPING A SURFACE PLASMA RESONANCE IMAGE -BASED IMMUNOBIOSENSOR FOR ASSESSING THE AFFINITY MATURATION OF ACETYLCHOLINE RECEPTOR ANTIBODIES IN MYASTHENIA GRAVIS
131	Munot, et.al.	Pinki	Congress 2/3	RITUXIMAB IN JUVENILE MYASTHENIA GRAVIS: A SINGLE CENTRE CASE SERIES
132	Muppidi, et.al.	Srikanth	Congress 2/3	DESIGN OF A DIGITAL SOLUTION TO IMPROVE MYASTHENIA GRAVIS PATIENT SYMPTOM TRACKING IN ROUTINE CLINICAL CARE

133	Muppidi, et.al.	Srikanth	Congress 2/3	EFFECT OF APPLYING INCLUSION AND EXCLUSION CRITERIA OF PHASE III MG CLINICAL TRIALS TO TERTIARY MG CENTER CLINICAL CARE
134	Muppidi, et.al.	Srikanth	Congress 2/3	OBSERVED EFFICACY OF EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS ACROSS PATIENT SUBGROUPS IN THE ADAPT-SC+ STUDY
135	Narayanaswami, et.al.	Pushpa	Congress 2/3	PROMISE-MG: LESSONS LEARNED
136	Narayanaswami, et.al.	Pushpa	Congress 2/3	EFFECTIVENESS AND SAFETY OF RAVULIZUMAB IN GENERALIZED MYASTHENIA GRAVIS: UPDATED REGISTRY ANALYSES
137	Narayanaswami, et.al.	Pushpa	Congress 2/3	SAFETY OUTCOMES IN PREGNANT PATIENTS TREATED WITH THE COMPLEMENT 5 INHIBITOR THERAPY ECULIZUMAB
138	Narayanaswami, et.al.	Pushpa	Congress 2/3	CHARACTERIZING AND QUANTIFYING IMPACTS OF GENERALIZED MYASTHENIA GRAVIS ON PATIENTS AND CAREGIVERS
139	Nowak, et.al.	Richard	Congress 2/3	CONCOMITANT IMMUNOSUPPRESSIVE THERAPY USE IN PATIENTS WITH GMG RECEIVING ECULIZUMAB OR RAVULIZUMAB

140	Narayanaswami, et.al.	Pushpa	Congress 2/3	UNDERSTANDING THE LIVED EXPERIENCES OF PEOPLE WITH GENERALISED MYASTHENIA GRAVIS AND THE IMPACT ON DAILY LIFE: A MIXED METHODS STUDY
141	Nelke, et.al.	Christopher	Congress 2/3	IDENTIFICATION OF DISEASE PHENOTYPES IN ACETYLCHOLINE RECEPTOR-ANTIBODY MYASTHENIA GRAVIS USING PROTEOMICS-BASED CONSENSUS CLUSTERING
142	Nowak, et.al.	Richard	Congress 2/3	MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): UNDERSTANDING THE IMPACT ON QUALITY-OF-LIFE
143	Nowak, et.al.	Richard	Congress 2/3	MYASTHENIA GRAVIS INEBILIZUMAB TRIAL (MINT): REDUCED RISK OF MG EXACERBATIONS, RESCUE THERAPY USE, AND CORTICOSTEROID BURDEN
144	Ntoukaki, et.al.	Eleni	Congress 2/3	MODIFICATIONS EXTENDING THE SERUM HALF-LIFE OF INTRAVENOUSLY ADMINISTERED ACETYLCHOLINE RECEPTOR A1 SUBUNIT EXTRACELLULAR DOMAIN RESULT IN IMPROVED THERAPEUTIC EFFICIENCY IN EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS
145	O'Connor, et.al.	Laura	Congress 2/3	CLINICAL COURSE OF MYASTHENIA GRAVIS IN PREGNANCY
146	Oved, et.al.	Kfir	Congress 2/3	MULTIPARAMETRIC ANALYSIS REVEALS TWO BIOLOGICALLY, EPIDEMIOLOGICALLY, CLINICALLY, AND SEX-SPECIFIC ENDOTYPES OF MYASTHENIA GRAVIS

147	Paardekooper, et.al.	Laurent	Congress 2/3	CHARACTERIZING THE (AUTOIMMUNE) B CELL EXPRESSION PROFILE OF MUSK MG PATIENTS
148	Paul, et.al.	Pritikanta	Congress 2/3	EMPOWERING UNDIAGNOSED MYASTHENIA GRAVIS (MG) PATIENTS: DESIGN OF A NOVEL ONLINE SELF-ASSESSMENT SCREENING TOOL
149	Pandya, et.al.	Shirali	Congress 2/3	INCIDENCE AND OUTCOME OF MENINGOCOCCAL INFECTION WITH ECULIZUMAB OR RAVULIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS OR NEUROMYELITIS OPTICA SPECTRUM DISORDER: AN ANALYSIS OF US CLINICAL PRACTICE
150	Pascuzzi, et.al.	Robert	Congress 2/3	EFFECT OF ROZANOLIXIZUMAB ON OCULAR SYMPTOMS: A POST HOC ITEM-LEVEL ANALYSIS OF MYASTHENIA GRAVIS-SPECIFIC OUTCOMES IN MYCARING
151	Pascuzzi, et.al.	Robert	Congress 2/3	EFFECT OF ROZANOLIXIZUMAB ON MYASTHENIA GRAVIS-SPECIFIC OUTCOME SUBDOMAIN SCORES: POST HOC ANALYSES FROM THE PHASE 3 MYCARING STUDY
152	Peng, et.al.	Siyang	Congress 2/3	THE RELEVANCE OF COMPLEMENT ACTIVATION IN MYASTHENIA GRAVIS – A QUANTIFICATION STUDY USING THE EXPERIMENTAL PASSIVE TRANSFER MYASTHENIA GRAVIS MODEL
153	Petersson, et.al.	Malin	Congress 2/3	BODY MASS INDEX AND PHYSICAL ACTIVITY AND RISK OF MYASTHENIA GRAVIS: RESULTS FROM THE SWEDISH GEMG-STUDY.

154	Punga, et.al.	Anna	Congress 2/3	DIGITAL PHENOTYPING OF PHYSICAL ACTIVITY AND SLEEP IN THE DIG-MG STUDY
155	Punga, et.al.	Anna	Congress 2/3	SENSITIVITY AND SPECIFICITY OF INFLAMMATORY PROTEIN BIOMARKERS IN ACETYLCHOLINE RECEPTOR ANTIBODY SEROPOSITIVE (ACHR+) MYASTHENIA GRAVIS
156	Ragole, et.al.	Thomas	Congress 2/3	INPATIENT TREATMENT OF MYASTHENIA GRAVIS EXACERBATION WITH EFGARTIGIMOD: A SINGLE ARM, OPEN LABEL PROSPECTIVE COHORT STUDY. PROTOCOL, RATIONALE AND EARLY RESULTS
157	Ragole, et.al.	Thomas	Congress 2/3	LIMITED RESPONSE TO PLASMAPHERESIS OR FCRN ANTAGONISM MAY PREDICT RESPONSE TO COMPLIMENT INHIBITION IN ACHR+ GENERALIZED MYASTHENIA GRAVIS: EXPERIENCE FROM A SINGLE CENTER
158	Ramdas, et.al.	Sithara	Congress 2/3	CLINICAL FEATURES, MANAGEMENT AND LONG TERM OUTCOME IN PAEDIATRIC ONSET MUSK-ASSOCIATED MYASTHENIA GRAVIS- A EUROPEAN COHORT STUDY
159	Ramdas, et.al.	Sithara	Congress 2/3	CROSS SECTIONAL STUDY OF 187 PATIENTS WITH CONGENITAL MYASTHENIA SYNDROME, DESCRIBING THE CLINICAL PHENOTYPES, GENETIC MUTATIONS, AND SINGLE POINT STANDARDISED ASSESSMENT SCORES
160	Reddel, et.al.	Stephen	Congress 2/3	RELIEVE: A PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF REMIBRUTINIB IN GENERALIZED MYASTHENIA GRAVIS

161	Reddel, et.al.	Stephen	Congress 2/3	MGBASE: A GLOBAL, OBSERVATIONAL REGISTRY FOR REAL-WORLD OUTCOMES RESEARCH IN MYASTHENIA GRAVIS
162	Remijn-Nelissen, et.al.	Linda	Congress 2/3	THE EFFICACY AND COST-UTILITY OF PYRIDOSTIGMINE IN PATIENTS WITH MYASTHENIA GRAVIS: A RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED CROSSOVER STUDY
163	Remijn-Nelissen, et.al.	Linda	Congress 2/3	THE EFFICACY, TOLERABILITY AND SAFETY OF AMIFAMPRIDINE IN PATIENTS WITH MYASTHENIA GRAVIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER STUDY
164	Reyes-Leiva, et.al.	David	Congress 2/3	MYASTHENIA GRAVIS CONTROL: EVOLUTION OVER EIGHT YEARS OF FOLLOW-UP IN A REFERRAL UNIT AND PATIENT CHARACTERISTICS
165	Rinaldi, et.al.	Elena	Congress 2/3	LIVE AChR AND MUSK CBA IDENTIFY POSITIVE AChR MG PATIENTS AMONG FIXED CBA NEGATIVE MG PATIENTS
166	Rossini, et.al.	Elena	Congress 2/3	COMPLEMENT INHIBITORS FOR MYASTHENIC CRISIS: A PROMISING AND FAST-ACTING THERAPY
167	Rossini, et.al.	Elena	Congress 2/3	RAVULIZUMAB TREATMENT FOR GENERALIZED MYASTHENIA GRAVIS: A MULTICENTER REAL-LIFE EXPERIENCE

168	Sacca, et.al.	Francesco	Congress 2/3	DIFFERENTIAL EFFECT OF ECULIZUMAB AND EFGARTIGIMOD ON SUBSCORES OF THE MG-ADL AND QMG IN GENERALIZED MYASTHENIA GRAVIS PATIENTS
169	Sacconi, et.al.	Sabrina	Congress 2/3	EFFECT OF ROZANOLIXIZUMAB ON BULBAR AND RESPIRATORY SYMPTOMS IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: POST HOC ITEM-LEVEL ANALYSIS OF MYCARING
170	Sacconi, et.al.	Sabrina	Congress 2/3	TOWARD EUROPEAN HARMONIZATION OF NATIONAL MYASTHENIA GRAVIS REGISTRIES: MODIFIED DELPHI PROCEDURE-BASED EXPERT CONSENSUS ON COLLECTABLE DATA
171	Salutto, et.al.	Valeria Lujan	Congress 2/3	MYASTHENIA GRAVIS IN LATIN AMERICA AND THE CARIBBEAN: EPIDEMIOLOGY, RESOURCES, AND ACCESSIBILITY TO DIAGNOSE AND TREATMENT
172	San, et.al.	Pyae Phy	Congress 2/3	DOMINANT T CELL EPITOPES AND CYTOKINE PROFILE IN IMMUNOTHERAPY NAÏVE ACHR MYASTHENIA GRAVIS
173	Sanabria, et.al.	Cristina	Congress 2/3	THYMOMATOUS MYASTHENIA GRAVIS IN A TEENAGER WHO DEVELOPED BREAST CANCER AFTER HIGH-DOSE RADIATION EXPOSURE: A CASE REPORT
174	Sato, et.al.	Mai	Congress 2/3	ASSESSING EFGARTIGIMOD DOSING PATTERNS AND MYASTHENIA GRAVIS ACTIVITIES OF DAILY LIVING OUTCOMES IN CLINICAL PRACTICE: RESULTS FROM A LARGE PATIENT SUPPORT PROGRAM DATABASE IN THE UNITED STATES

175	Scheiner, et.al.	Christopher	Congress 2/3	OUTCOMES WITH RAVULIZUMAB OR EFGARTIGIMOD IN GMG: A RETROSPECTIVE MEDICAL RECORD ANALYSIS
176	Schiavo, et.al.	Ebe	Congress 2/3	ACETYLCHOLINE RECEPTOR ANTIBODIES ISOFORM SPECIFICITY: A POTENTIAL PROGNOSTIC BIOMARKER IN MYASTHENIA GRAVIS
177	Schiavolin, et.al.	Mattia	Congress 2/3	CLINICAL CHARATERISTICS AND MANAGEMENT OF IMMUNOTHERAPY IN SERONEGATIVE MYASTHENIA GRAVIS: A SYSTEMATIC REVIEW OF THE LITERATURE
178	Huntemann, et.al.	Niklas	Congress 2/3	ITIH3: A SERUM BIOMARKER FOR DISEASE ACTIVITY IN MYASTHENIA GRAVIS
179	Schwaede, et.al.	Abigail	Congress 2/3	STUDY DESIGN OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN JUVENILE GENERALIZED MYASTHENIA GRAVIS
180	Seddik, et.al.	Kenza	Congress 2/3	EXPLORATORY QUALITATIVE STUDY OF THE EXPERIENCES OF WOMEN LIVING WITH MYASTHENIA GRAVIS
181	Seo, et.al.	Dongjin	Congress 2/3	STEROID SPARING EFFECT OF TACROLIMUS IN ANTI-MUSK ANTIBODY POSITIVE MYASTHENIA GRAVIS

182	Shownkeen, et.al.	Meghana	Congress 2/3	COMBINED USE OF ZILUCOPLAN AND RITUXIMAB FOR ACETYLCHOLINE RECEPTOR ANTIBODY POSITIVE (ACHR+) GENERALIZED MYASTHENIA GRAVIS
183	Siddiqi, et.al.	Zaeem	Congress 2/3	RESIDUAL SERUM FIBRINOGEN AS A UNIVERSAL BIOMARKER FOR ALL SEROTYPES OF MYASTHENIA GRAVIS
184	Sikorski, et.al.	Patricia	Congress 2/3	SERUM PROFILING REVEALS PROTEOMIC CHANGES ASSOCIATED WITH THE IMMUNE SYSTEM AND SIGNAL TRANSDUCTION IN MYASTHENIA GRAVIS
185	Smith, et.al.	Gordon	Congress 2/3	EVALUATING THE COMPARATIVE EFFECTIVENESS OF EMERGING IMMUNOMODULATORY THERAPIES FOR PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
186	Sobieszczuk, et.al.	Ewa	Congress 2/3	HIGHER RISK OF FRACTURES IN MYASTHENIA GRAVIS PATIENTS IN COMPARISON WITH GENERAL POPULATION- HEALTHCARE DATABASE STUDY
187	Sobieszczuk, et.al.	Ewa	Congress 2/3	MYASTHENIC CRISIS – 15-YEARS' EXPERIENCE OF REFERENCE NEUROMUSCULAR CENTER
188	Sosa Marmol, et.al.	Sofia Maria	Congress 2/3	OPTIMISATION OF MESENCHYMAL STROMAL CELLS CONDITIONING IN PERSPECTIVE OF A TREATMENT FOR MYASTHENIA GRAVIS

189	Stascheit, et.al.	Frauke	Congress 2/3	A GENOME WIDE ASSOCIATION STUDY OF MYASTHENIA GRAVIS UNCOVERS NEW LOCI AND GIVES FIRST INSIGHTS INTO THE PERFORMANCE OF POLYGENIC PREDICTION PREDICTION
190	Steeland, et.al.	Sophie	Congress 2/3	EFFECT OF INTRAVENOUS AND SUBCUTANEOUS EFGARTIGIMOD ON MG-ADL AND QMG SUBDOMAINS IN THE ADAPT-SC STUDY IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS
191	Steeland, et.al.	Sophie	Congress 2/3	COMBINED ANALYSES OF PARTICIPANTS WITH ANTI-ACETYLCHOLINE RECEPTOR SERONEGATIVE GENERALIZED MYASTHENIA GRAVIS TREATED WITH EFGARTIGIMOD ACROSS CLINICAL STUDIES
192	Steyaert, et.al.	Christophe	Congress 2/3	STRUCTURE-FUNCTION ANALYSIS OF ARGX-119, A FIRST-IN-CLASS HUMANIZED AGONIST MONOCLONAL ANTIBODY SPECIFIC FOR MUSCLE-SPECIFIC KINASE
193	Teranishi, et.al.	Hirofumi	Congress 2/3	SAFETY AND EFFECTIVENESS OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS IN JAPAN: INTERIM ANALYSIS OF POST-MARKETING SURVEILLANCE DATA
194	Trinh, et.al.	Vu	Congress 2/3	AN ANTIGEN-SPECIFIC CHIMERIC AUTOANTIBODY RECEPTOR T CELL STRATEGY FOR THE ELIMINATION OF ANTI-MAIN IMMUNOGENIC REGION ANTIBODY-SECRETING B CELLS
195	Truffault, et.al.	Frédérique	Congress 2/3	JUVENILE MYASTHENIA GRAVIS IN A FRENCH COHORT: FOCUS ON THYMIC HISTOLOGY

196	Tuulasvaara, et.al.	Anni	Congress 2/3	DIFFERENCES BETWEEN FEMALES AND MALES IN THE DIAGNOSTIC DELAY AND CLINICAL COURSE OF THYMECTOMISED MYASTHENIA GRAVIS
197	Tzartos, et.al.	John	Congress 2/3	EFFICIENCY OF THE FIXED- AND LIVE-CELL-BASED ASSAYS TO DETECT ACHR ANTIBODIES IN MG SERA WITH LOW ANTIBODY CONCENTRATIONS AS DETERMINED BY RADIOIMMUNOPRECIPITATION ASSAY
198	Uysal, et.al.	Sanem	Congress 2/3	FREQUENCY AND SEVERITY OF MYASTHENIA GRAVIS EXACERBATIONS ASSOCIATED WITH THE USE OF CIPROFLOXACIN, LEVOFLOXACIN AND AZITHROMYCIN
199	van Bragt, et.al.	Tonke	Congress 2/3	FIRST-IN-HUMAN DOSE SELECTION AND PHARMACOKINETICS, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF ARGX-119, AN AGONIST ANTIBODY FOR HUMAN MUSCLE-SPECIFIC KINASE
200	Vergoossen, et.al.	Dana	Congress 2/3	MUSK ANTIBODIES DIFFERENTLY AFFECT THE MUSK SIGNALING CASCADE DEPENDING ON VALENCY AND EPITOPE
201	Verhagen, et.al.	Eline	Congress 2/3	FAMILIAL AUTOIMMUNITY IN MYASTHENIA GRAVIS
202	Verpalen, et.al.	Robyn	Congress 2/3	BUILDING AN INDUCED PLURIPOTENT STEM CELL-BASED THREE-DIMENSIONAL NEUROMUSCULAR JUNCTION ON A CHIP: A NOVEL MODEL TO STUDY NEUROMUSCULAR DISEASE

203	Verza, et.al.	Massimiliano Ugo	Congress 2/3	VALIDATION OF THE “PATIENT-ACCEPTABLE SYMPTOM STATE” QUESTION AS OUTCOME MEASURE IN ACHR MG: A MULTICENTER, PROSPECTIVE STUDY
204	Vesperinas, et.al.	Ana	Congress 2/3	MG MIMICS: ANALYSIS OF THE DIAGNOSTIC PROCESS IN A SPECIALIZED MYASTHENIA GRAVIS CLINIC
205	Vesperinas, et.al.	Ana	Congress 2/3	DEVELOPMENT OF A MOBILE APPLICATION FOR MONITORING PATIENTS WITH MYASTHENIA GRAVIS: RESULTS FROM THE FIRST SIX MONTHS
206	Vu, et.al.	Tuan	Congress 2/3	RESPONDER AND MINIMAL SYMPTOM EXPRESSION RATES WITH ROZANOLIXIZUMAB IN GENERALISED MYASTHENIA GRAVIS: FINAL POOLED ANALYSIS OF PHASE 3 STUDIES
207	Vu, et.al.	Tuan	Congress 2/3	NON-STEROIDAL IMMUNOSUPPRESSANT THERAPY CHANGES DURING ZILUCOPLAN TREATMENT IN GENERALISED MYASTHENIA GRAVIS: 120-WEEK FOLLOW-UP OF RAISE-XT
208	Vu, et.al.	Tuan	Congress 2/3	LONG-TERM SAFETY AND EFFICACY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN ADULT PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT-SC+ STUDY
209	Vu, et.al.	Tuan	Congress 2/3	COVID-19 VACCINATION RESPONSE IN PARTICIPANTS ACROSS CLINICAL TRIALS INVESTIGATING EFGARTIGIMOD IV AND EFGARTIGIMOD PH20 SC

210	Wang, et.al.	Yuan	Congress 2/3	CLINICAL CHARACTERISTICS IN MYASTHENIA GRAVIS WITH IN-HOSPITAL MORTALITY AND THE ETIOLOGY ANALYSIS
211	Webster, et.al.	Richard	Congress 2/3	MUSK AGONIST ANTIBODY DID NOT SUCCEED TO RESCUE PHENOTYPE OF ACHR DEFICIENCY CONGENITAL MYASTHENIC SYNDROME (CMS) MOUSE MODEU
212	Wiendl, et.al.	Heinz	Congress 2/3	EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: STUDY DESIGN
213	Wiendl, et.al.	Heinz	Congress 2/3	SAFETY OF REMIBRUTINIB ACROSS IMMUNE-MEDIATED DISEASES
214	Wilf-Yarkoni, et.al.	Adi	Congress 2/3	INCREASED PREVALENCE OF EXTRATHYMIC NEOPLASM IN MYASTHENIA GRAVIS PATIENTS FROM CLALIT MACHINE-LEARNING REGISTRY
215	Wong, et.al.	Sui H	Congress 2/3	MULTICENTER VALIDATION OF THE OCULAR MYASTHENIA GRAVIS RATING SCALE QUESTIONNAIRE
216	Wu, et.al.	Hui	Congress 2/3	ECULIZUMAB AS A NEW OPTION FOR PERIOPERATIVE TREATMENT IN THYMOMA-ASSOCIATED MYASTHENIA GRAVIS: A PROSPECTIVE CASE SERIES

217	Wu, et.al.	Wanqing	Congress 2/3	THE SWEDISH MYASTHENIA GRAVIS REGISTRY: A NATIONWIDE, POPULATION-BASED HIGH COVERAGE REGISTRY
218	Wu, et.al.	Jing	Congress 2/3	WHO WOULD BENEFIT FROM THYMECTOMY IN NON-THYMOMATOUS MYASTHENIA GRAVIS? A MULTICENTER STUDY FROM NORDIC COUNTRIES
219	Yan, et.al.	Chong	Congress 2/3	INITIAL COMBINATION THERAPY OF TACROLIMUS AND EFGARTIGIMOD INDUCE MINIMAL SYMPTOM EXPRESSION IN NEW-ONSET GENERALIZED MYASTHENIA GRAVIS: A SINGLE-CENTER, REAL-WORLD CASE SERIES
220	Zara, et.al.	Pietro	Congress 2/3	RISK AND DETERMINANTS OF “FALSE” ACETYLCHOLINE RECEPTOR AUTOANTIBODY POSITIVITY BY RADIOIMMUNOPRECIPITATION ASSAY IN A REAL-LIFE SETTING
221	Zhong, et.al.	Huahua	Congress 2/3	GRO CHEMOKINES-INDUCED NEUTROPHIL EXTRACELLULAR TRAP CITH3 AS A NEW BIOMARKER RELATED TO MG SEVERITY
222	Zhou, et.al.	Yufan	Congress 2/3	EFGARTIGIMOD FOR INDUCTION AND MAINTENANCE THERAPY IN MUSCLE-SPECIFIC KINASE MYASTHENIA GRAVIS: A MULTI-CENTER STUDY
223	Zhou, et.al.	Yufan	Congress 2/3	RESPONSE TO SINGLE LOW-DOSE RITUXIMAB COULD PREDICT BETTER MULTI-CYCLE TREATMENT OUTCOME IN REFRACTORY MYASTHENIA GRAVIS: A SINGLE-CENTER COHORT STUDY

224	Zweig, et.al.	Aaron	Congress 2/3	TREATMENT REFRACTORY LRP4-ANTIBODY POSITIVE MYASTHENIA GRAVIS RESPONSIVE TO EFGARTIGIMOD ALFA INFUSION
-----	---------------	-------	--------------	---